Literature DB >> 20638934

Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation.

Tao Yang1, Ping Yang, Dan M Roden, Dawood Darbar.   

Abstract

BACKGROUND: Emerging evidence has strongly implicated hereditary determinants for atrial fibrillation (AF). Loss-of-function mutations in KCNA5 encoding the ultrarapid delayed rectifier potassium current I(Kur) have been identified in AF families.
OBJECTIVE: The purpose of this study was to determine the clinical and biophysical phenotypes in a KCNA5 mutation with deletion of 11 amino acids in the N-terminus of the protein, which was identified in patients with lone AF.
METHODS: Patients with AF confirmed by ECG were prospectively enrolled in the Vanderbilt AF Registry, which comprises clinical and genetic databases. A KCNA5 mutation was generated by mutagenesis for electrophysiologic characterization.
RESULTS: We identified a novel 33-bp coding region deletion in two Caucasian probands. One proband was part of a kindred that included four other members with AF, and all were mutation carriers. The mutation results in deletion of 11 amino acids in the N-terminus of the protein, a proline-rich region as a binding site for Src homology 3 (SH3) domains associated with Src-family protein tyrosine kinase (TK) pathway. In transfected cells, the mutant caused approximately 60% decreased I(Kur) versus wild-type (WT) (75 +/- 8 pA/pF vs 180 +/- 15 pA/pF, P <.01) and dominant-negative effect on WT current (105 +/- 10 pA/pF, P <.01). Pretreatment with the Src inhibitor PP2 prevented v-Src TK from 90% suppressed WT current. In contrast, the mutant channel displayed no response to v-Src TK.
CONCLUSION: Our data implicate abnormal atrial repolarization control due to variable TK signaling as a mechanism in familial AF and thereby suggest a role for modulation of this pathway in AF and its treatment. Copyright 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KCNA5 channel; familial atrial fibrillation; genetics; tyrosine kinase; variants

Mesh:

Substances:

Year:  2010        PMID: 20638934      PMCID: PMC2932792          DOI: 10.1016/j.hrthm.2010.05.032

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  37 in total

1.  Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions.

Authors:  Tao Yang; Hideaki Kanki; Dan M Roden
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

Review 2.  New ideas about atrial fibrillation 50 years on.

Authors:  Stanley Nattel
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

4.  Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.

Authors:  T Ueyama; S Kawashima; T Sakoda; Y Rikitake; T Ishida; M Kawai; T Yamashita; S Ishido; H Hotta; M Yokoyama
Journal:  J Mol Cell Cardiol       Date:  2000-06       Impact factor: 5.000

Review 5.  Electrophysiological remodeling in human atrial fibrillation.

Authors:  David R Van Wagoner
Journal:  Pacing Clin Electrophysiol       Date:  2003-07       Impact factor: 1.976

6.  A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation.

Authors:  Takeru Makiyama; Masaharu Akao; Satoshi Shizuta; Takahiro Doi; Kei Nishiyama; Yuko Oka; Seiko Ohno; Yukiko Nishio; Keiko Tsuji; Hideki Itoh; Takeshi Kimura; Toru Kita; Minoru Horie
Journal:  J Am Coll Cardiol       Date:  2008-10-14       Impact factor: 24.094

7.  A structural requirement for processing the cardiac K+ channel KCNQ1.

Authors:  Hideaki Kanki; Sabina Kupershmidt; Tao Yang; Sam Wells; Dan M Roden
Journal:  J Biol Chem       Date:  2004-05-12       Impact factor: 5.157

8.  Familial atrial fibrillation is a genetically heterogeneous disorder.

Authors:  Dawood Darbar; Kathleen J Herron; Jeffrey D Ballew; Arshad Jahangir; Bernard J Gersh; Win-K Shen; Stephen C Hammill; Douglas L Packer; Timothy M Olson
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

9.  KCNQ1 gain-of-function mutation in familial atrial fibrillation.

Authors:  Yi-Han Chen; Shi-Jie Xu; Said Bendahhou; Xiao-Liang Wang; Ying Wang; Wen-Yuan Xu; Hong-Wei Jin; Hao Sun; Xiao-Yan Su; Qi-Nan Zhuang; Yi-Qing Yang; Yue-Bin Li; Yi Liu; Hong-Ju Xu; Xiao-Fei Li; Ning Ma; Chun-Ping Mou; Zhu Chen; Jacques Barhanin; Wei Huang
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

10.  Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome.

Authors:  Paulus Kirchhof; Lars Eckardt; Michael R Franz; Gerold Mönnig; Peter Loh; Horst Wedekind; Eric Schulze-Bahr; Günther Breithardt; Wilhelm Haverkamp
Journal:  J Cardiovasc Electrophysiol       Date:  2003-10
View more
  29 in total

Review 1.  Emerging directions in the genetics of atrial fibrillation.

Authors:  Nathan R Tucker; Patrick T Ellinor
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 2.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

Review 3.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

4.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

5.  Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase.

Authors:  Guo-Sheng Xiao; Yan-Hui Zhang; Wei Wu; Hai-Ying Sun; Yan Wang; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2017-02-09       Impact factor: 8.739

Review 6.  Genetics of atrial fibrillation: from families to genomes.

Authors:  Ingrid E Christophersen; Patrick T Ellinor
Journal:  J Hum Genet       Date:  2015-05-21       Impact factor: 3.172

Review 7.  Genotype influence in responses to therapy for atrial fibrillation.

Authors:  Henry Huang; Dawood Darbar
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-07-15

8.  Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation.

Authors:  Marylyn D Ritchie; Shane Rowan; Gayle Kucera; Tanya Stubblefield; Marcia Blair; Shannon Carter; Dan M Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-07-18       Impact factor: 24.094

9.  Atrial Fibrillation and SCN5A Variants.

Authors:  Eleonora Savio-Galimberti; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

Review 10.  A contemporary review on the genetic basis of atrial fibrillation.

Authors:  Jason D Roberts; Michael H Gollob
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.